HHS Gives FDA Responsibility for Checking ClinicalTrials.gov Accuracy
The FDA will begin policing compliance with clinical trial submission requirements for ClinicalTrials.gov under a policy change at HHS. Previously, HHS verified the completeness and accuracy of the information on the site.
A late-September FederalRegister notice states the responsibility has now transferred to the FDA and charges the agency with identifying incorrect or fraudulent submissions and seeking out unsubmitted trial results. The FDA is directed to notify sponsors who haven’t submitted results and demand that they do so within 30 days. The agency will not receive any additional funding for the new responsibility and will use existing appropriations to carry out related tasks.
The NIH maintains ClinicalTrials.gov, a clinical trial registry data bank, in accordance with the Public Health Service Act. However, academic studies — including a prominent study published in the January 2012 BritishMedicalJournal — found that as few as 22 percent of completed studies are added to the database as required. That report created a new public push for compliance.
Are you compliant when registering your trials on ClinicalTrials.gov? New legislation is also pending in the House to increase reporting requirements and also step up penalties. When the inevitable compliance hammer falls, will you be crushed, bruised or completely out of harm’s way?
Come for this valuable opportunity to hear FDA officials discuss regulatory plans and objectives — and ask questions you need answered; learn from device industry experts, consultants and other experts with actionable tips and strategies you can take straight back to the office; and network with other professionals who understand your challenges; share war stories and insights over a drink. Register Today.Read More
The FDA's new enforcement plan makes one thing clear: Developing a successful CAPA program has never been more important. But creating an FDA-proof CAPA isn’t easy. If only you could pick the brain of someone who is coping successfully with CAPA — the best and the brightest, an industry leader who has devised programs, procedures and solutions that have put companies out in front with the FDA. Well, you can. Register today.Read More
The FDA’s cadre of freshly trained inspectors — many of whom come directly from industry — and increased focus on specialized inspections are making it harder than ever to predict the outcome of your next FDA inspection. Unless, of course, you have Surviving an FDA Inspection at your fingertips. If you could spend less than $400 to get your drug manufacturing facility fully prepared to face a tough inspection by the FDA, would you even hesitate? ... Of course not!